Biomarck Competitors and Similar CompaniesClear all
Biomarck's competitors and similar companies include Omeros, CureVac, CytomX Therapeutics and Puma Biotechnology.
 Omeros Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers. |  CytomX Therapeutics CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform. |  Puma Biotechnology Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer. | |||
Founding Date | Founding Date 2002 | Founding Date 1994 | Founding Date 2000 | Founding Date 2008 | Founding Date 2010 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Newtown, US HQ | Locations Seattle, US HQ | Locations Tübingen, DE HQ Ottignies Louvain La Neuve, BE Wiesbaden, DE Amsterdam, NL Basel, CH Boston, US | Locations South San Francisco, US HQ | Locations Los Angeles, US HQ |
Employees | Employees 1115% decrease | Employees 1968% decrease | Employees 82517% decrease | Employees 15815% increase | Employees 27214% decrease |
Valuation ($) | Valuation ($) N/A | Valuation ($) 248.6 m | Valuation ($) 648.3 m | Valuation ($) 78 m | Valuation ($) 136.8 m |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) N/A | Revenue (est.) €535.2m (FY, 2024) | Revenue (est.) $76.2m (FY, 2025) | Revenue (est.) $228.4m (FY, 2025) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods €9.7m (FY, 2024) | Cost of goods N/A | Cost of goods $58.2m (FY, 2025) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit €534.4m (FY, 2024) | Gross profit N/A | Gross profit $170.2m (FY, 2025) |
Net income | Net income N/A | Net income ($3.4m) (FY, 2025) | Net income €162.2m (FY, 2024) | Net income ($17.4m) (FY, 2025) | Net income N/A |
Operating ⚠ | |||||
Patents (Foreign) | Patents (Foreign) N/A | Patents (Foreign) 1 (FY, 2021) | Patents (Foreign) N/A | Patents (Foreign) 4 (FY, 2016) | Patents (Foreign) N/A |
Patents (US) | Patents (US) N/A | Patents (US) 80 (FY, 2021) | Patents (US) N/A | Patents (US) 13 (FY, 2016) | Patents (US) N/A |
Phase I Trials Products | Phase I Trials Products N/A | Phase I Trials Products 3 (FY, 2021) | Phase I Trials Products 3 (May, 2020) | Phase I Trials Products 1 (FY, 2016) | Phase I Trials Products N/A |
Funding | |||||
Total funding raised | Total funding raised $ 751.3k | Total funding raised $ 354.8m | Total funding raised $ 1.1b | Total funding raised $ 132.4m | Total funding raised $ 172m |
For sources of this data, please see the company profile
View Company Profiles
Omeros
HQ
Seattle, US
Employees
196↓ 8% decrease
Omeros Corporation is a biopharmaceutical company developing products focused on inflammation and central nervous system disorders as well as immune-related diseases, including cancers.
View company
CureVac
HQ
Tübingen, DE
Employees
825↓ 17% decrease
CureVac is a biotechnology company offering messenger RNA (mRNA) technology.
View companyCytomX Therapeutics
HQ
South San Francisco, US
Employees
158↑ 15% increase
CytomX is an oncology-focused biopharmaceutical company pioneering a novel class of antibody therapeutics based on Probody technology platform.
View companyPuma Biotechnology
HQ
Los Angeles, US
Employees
272↓ 14% decrease
Puma Biotechnology acquires and develops innovative products for the treatment of various forms of cancer.
View company